Eisai Submits Aricept Application in Japan

Eisai has submitted a marketing and manufacturing authorisation application in Japan to seek approval of a new dry syrup formulation of Aricept.

Eisai has submitted a marketing and manufacturing authorisation application in Japan to seek approval of a new dry syrup formulation of its Alzheimer's disease treatment Aricept (donepezil hydrochloride).

In August 2007, the indication of Aricept was expanded to include severe Alzheimer’s disease. The simultaneous approval of additional daily dosage to a maximum of 10mg also made it possible to adjust Aricept dosage amounts.

This latest version of Aricept is a dry syrup formulation that can be administered by suspending dry syrup powder with water, which allows dosage to be adjusted within approved dosage amounts at the time of administration depending on the needs of individual patients. It was designed as a suspension to make it easier for patients who find powder t